255 related articles for article (PubMed ID: 11319174)
1. Serum enterolactone and risk of breast cancer: a case-control study in eastern Finland.
Pietinen P; Stumpf K; Männistö S; Kataja V; Uusitupa M; Adlercreutz H
Cancer Epidemiol Biomarkers Prev; 2001 Apr; 10(4):339-44. PubMed ID: 11319174
[TBL] [Abstract][Full Text] [Related]
2. Plasma enterolactone and genistein and the risk of premenopausal breast cancer.
Piller R; Chang-Claude J; Linseisen J
Eur J Cancer Prev; 2006 Jun; 15(3):225-32. PubMed ID: 16679865
[TBL] [Abstract][Full Text] [Related]
3. Plasma enterolactone and breast cancer incidence by estrogen receptor status.
Olsen A; Knudsen KE; Thomsen BL; Loft S; Stripp C; Overvad K; Møller S; Tjønneland A
Cancer Epidemiol Biomarkers Prev; 2004 Dec; 13(12):2084-9. PubMed ID: 15598765
[TBL] [Abstract][Full Text] [Related]
4. Serum enterolactone concentration is not associated with prostate cancer risk in a nested case-control study.
Kilkkinen A; Virtamo J; Virtanen MJ; Adlercreutz H; Albanes D; Pietinen P
Cancer Epidemiol Biomarkers Prev; 2003 Nov; 12(11 Pt 1):1209-12. PubMed ID: 14652283
[TBL] [Abstract][Full Text] [Related]
5. Urinary phytoestrogens and postmenopausal breast cancer risk.
den Tonkelaar I; Keinan-Boker L; Veer PV; Arts CJ; Adlercreutz H; Thijssen JH; Peeters PH
Cancer Epidemiol Biomarkers Prev; 2001 Mar; 10(3):223-8. PubMed ID: 11303591
[TBL] [Abstract][Full Text] [Related]
6. Reliability of serum measurements of lignans and isoflavonoid phytoestrogens over a two-year period.
Zeleniuch-Jacquotte A; Adlercreutz H; Akhmedkhanov A; Toniolo P
Cancer Epidemiol Biomarkers Prev; 1998 Oct; 7(10):885-9. PubMed ID: 9796633
[TBL] [Abstract][Full Text] [Related]
7. Serum enterolactone concentration is not associated with breast cancer risk in a nested case-control study.
Kilkkinen A; Virtamo J; Vartiainen E; Sankila R; Virtanen MJ; Adlercreutz H; Pietinen P
Int J Cancer; 2004 Jan; 108(2):277-80. PubMed ID: 14639615
[TBL] [Abstract][Full Text] [Related]
8. Enterolactone is differently associated with estrogen receptor beta-negative and -positive breast cancer in a Swedish nested case-control study.
Sonestedt E; Borgquist S; Ericson U; Gullberg B; Olsson H; Adlercreutz H; Landberg G; Wirfält E
Cancer Epidemiol Biomarkers Prev; 2008 Nov; 17(11):3241-51. PubMed ID: 18990767
[TBL] [Abstract][Full Text] [Related]
9. Dietary phytoestrogen, serum enterolactone and risk of prostate cancer: the cancer prostate Sweden study (Sweden).
Hedelin M; Klint A; Chang ET; Bellocco R; Johansson JE; Andersson SO; Heinonen SM; Adlercreutz H; Adami HO; Grönberg H; Bälter KA
Cancer Causes Control; 2006 Mar; 17(2):169-80. PubMed ID: 16425095
[TBL] [Abstract][Full Text] [Related]
10. An incident case-referent study on plasma enterolactone and breast cancer risk.
Hultén K; Winkvist A; Lenner P; Johansson R; Adlercreutz H; Hallmans G
Eur J Nutr; 2002 Aug; 41(4):168-76. PubMed ID: 12242585
[TBL] [Abstract][Full Text] [Related]
11. Risk of cardiovascular disease-related and all-cause death according to serum concentrations of enterolactone: Kuopio Ischaemic Heart Disease Risk Factor Study.
Vanharanta M; Voutilainen S; Rissanen TH; Adlercreutz H; Salonen JT
Arch Intern Med; 2003 May; 163(9):1099-104. PubMed ID: 12742810
[TBL] [Abstract][Full Text] [Related]
12. Insulin-like growth factor I (IGF-I), IGF-binding proteins, and breast cancer.
Krajcik RA; Borofsky ND; Massardo S; Orentreich N
Cancer Epidemiol Biomarkers Prev; 2002 Dec; 11(12):1566-73. PubMed ID: 12496045
[TBL] [Abstract][Full Text] [Related]
13. Serum enterolactone and prognosis of postmenopausal breast cancer.
Buck K; Vrieling A; Zaineddin AK; Becker S; Hüsing A; Kaaks R; Linseisen J; Flesch-Janys D; Chang-Claude J
J Clin Oncol; 2011 Oct; 29(28):3730-8. PubMed ID: 21900115
[TBL] [Abstract][Full Text] [Related]
14. Changes in serum enterolactone, genistein, and daidzein in a dietary intervention study in Finland.
Stumpf K; Pietinen P; Puska P; Adlercreutz H
Cancer Epidemiol Biomarkers Prev; 2000 Dec; 9(12):1369-72. PubMed ID: 11142423
[TBL] [Abstract][Full Text] [Related]
15. Serum enterolactone concentration and the risk of coronary heart disease in a case-cohort study of Finnish male smokers.
Kilkkinen A; Erlund I; Virtanen MJ; Alfthan G; Ariniemi K; Virtamo J
Am J Epidemiol; 2006 Apr; 163(8):687-93. PubMed ID: 16510545
[TBL] [Abstract][Full Text] [Related]
16. Inverse association between dietary and serum conjugated linoleic acid and risk of breast cancer in postmenopausal women.
Aro A; Männistö S; Salminen I; Ovaskainen ML; Kataja V; Uusitupa M
Nutr Cancer; 2000; 38(2):151-7. PubMed ID: 11525591
[TBL] [Abstract][Full Text] [Related]
17. Circulating enterolactone and risk of breast cancer: a prospective study in New York.
Zeleniuch-Jacquotte A; Adlercreutz H; Shore RE; Koenig KL; Kato I; Arslan AA; Toniolo P
Br J Cancer; 2004 Jul; 91(1):99-105. PubMed ID: 15226762
[TBL] [Abstract][Full Text] [Related]
18. Serum enterolactone and postmenopausal breast cancer risk by estrogen, progesterone and herceptin 2 receptor status.
Zaineddin AK; Vrieling A; Buck K; Becker S; Linseisen J; Flesch-Janys D; Kaaks R; Chang-Claude J
Int J Cancer; 2012 Mar; 130(6):1401-10. PubMed ID: 21544804
[TBL] [Abstract][Full Text] [Related]
19. Serum enterolactone levels and mortality outcome in women with early breast cancer: a retrospective cohort study.
Guglielmini P; Rubagotti A; Boccardo F
Breast Cancer Res Treat; 2012 Apr; 132(2):661-8. PubMed ID: 22094938
[TBL] [Abstract][Full Text] [Related]
20. Dietary determinants of plasma enterolactone.
Horner NK; Kristal AR; Prunty J; Skor HE; Potter JD; Lampe JW
Cancer Epidemiol Biomarkers Prev; 2002 Jan; 11(1):121-6. PubMed ID: 11815409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
